Autologous blood-derived products (ABDPs)—notably platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and plasma albumin-based gels—are presented as point-of-care biologics that amplify endogenous repair while permitting standardized manufacture. The chapter defines classifications and nomenclature, details the physics of differential centrifugation (relative centrifugal force, rotor geometry, time), anticoagulant handling, and strategies to control leukocytes and red cells, and maps activation modes and release kinetics to clinical intent. Mechanistic sections connect paracrine signaling, angiogenesis, extracellular-matrix remodeling, and immunomodulation with histologic and instrumented outcomes. Indication-specific protocols are summarized across dermatology and aesthetic rejuvenation, oral and maxillofacial surgery (periodontal and peri-implant regeneration, ridge preservation, sinus augmentation, guided bone regeneration), endodontic revitalization, orthodontic tooth-movement acceleration, and temporomandibular disorders. Practical algorithms emphasize matching product phenotype, dose, and kinetics to target tissues; optimizing delivery depth and timing; and integrating ABDPs with biomaterial scaffolds (e.g., “sticky bone”) and peri-implant soft-tissue augmentation. Safety, contraindications, and risk mitigation are addressed, alongside quality control and composition reporting (e.g., DEPA) to improve reproducibility and evidence synthesis. The chapter concludes with research priorities in standardization, dose–response modeling, and comparative effectiveness.